Abstract: Provided in the present disclosure is the use of an SARM1 enzyme activity inhibitor in the treatment of neurodegenerative diseases or neurological diseases or conditions, and in particular, provided in the present invention are a compound represented by formula (a) as an SARM1 enzyme activity inhibitor, and a pharmaceutical composition thereof.

Abstract: Silane-modified polyether sealant and preparation methods and uses thereof The silane-modified polyether sealant includes the following raw materials: a silane-modified polyether resin, a plasticizer, a drilling agent, a filler, an adhesion promoter and a catalyst. In the present invention, various coupling agents are hydrolyzed and cross-linked to form an oligomer as the adhesion promoter. Compared with ordinary silane coupling agents, the oligomer coupling agent has higher activity to promote deep curing of the adhesive. In addition, compared with ordinary catalysts, the catalyst prepared by the present invention has higher catalytic activity. It accelerates the hydrolysis, crosslinking and curing of the adhesive, thus helping to obtain a uniformly dispersed, thixotropic single-component silane-modified polyether sealant.